BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31897588)

  • 1. Usefulness of [
    Zhao L; Zhuang Y; Fu K; Chen P; Wang Y; Zhuo J; Liao X; Chen H; Lin Q
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1065-1074. PubMed ID: 31897588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between the expression of PD-L1 and
    Li J; Chen R; Chen Y; Xia Q; Zhou X; Xia Q; Wang C; Wan L; Bao H; Huang G; Liu J
    Br J Cancer; 2023 Aug; 129(3):541-550. PubMed ID: 37311977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of early evaluation of treatment response using
    Chen YH; Chang KP; Chu SC; Yen TC; Wang LY; Chang JT; Hsu CL; Ng SH; Liu SH; Chan SC
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):650-660. PubMed ID: 30264225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.
    Chan SC; Chang KP; Fang YD; Tsang NM; Ng SH; Hsu CL; Liao CT; Yen TC
    Laryngoscope; 2017 Jan; 127(1):E22-E28. PubMed ID: 27435352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment
    Lin HC; Chan SC; Cheng NM; Liao CT; Hsu CL; Wang HM; Lin CY; Chang JT; Ng SH; Yang LY; Yen TC
    Oral Oncol; 2020 May; 104():104628. PubMed ID: 32163890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation between PD-L1 expression and metabolic parameters of
    Xu X; Li J; Yang Y; Sang S; Deng S
    Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Pretreatment
    Yao J; Wang Y; Lin Y; Yang Y; Wan J; Gong X; Zhang F; Zhang W; Marks T; Wang S; Jin H; Shan H
    Drug Des Devel Ther; 2021; 15():4157-4166. PubMed ID: 34621120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
    Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
    PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy.
    Alessi A; Lorenzoni A; Cavallo A; Padovano B; Iacovelli NA; Bossi P; Alfieri S; Serafini G; Colombo CB; Cicchetti A; Mira M; Licitra L; Fallai C; Crippa F; Orlandi E
    Radiol Med; 2019 May; 124(5):414-421. PubMed ID: 30560502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic utility of (18)F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging biomarker site.
    Lin P; Min M; Lee M; Holloway L; Forstner D; Bray V; Xuan W; Chicco A; Fowler A
    Radiother Oncol; 2016 Jul; 120(1):87-91. PubMed ID: 27321151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selectively recommend
    Chen C; Xu T; Qiu X; Xie S; You Z; Hu Y; Zheng Y; Liang Z; Huang C; Chen T; Li L; Liu J; Fei Z
    Radiat Oncol; 2021 Nov; 16(1):229. PubMed ID: 34838075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma.
    Chang KP; Tsang NM; Liao CT; Hsu CL; Chung MJ; Lo CW; Chan SC; Ng SH; Wang HM; Yen TC
    J Nucl Med; 2012 Jan; 53(1):21-8. PubMed ID: 22213820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.
    Zhou X; Hu Y; Sun H; Chen R; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3107-3115. PubMed ID: 37147479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
    Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
    Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[
    Wu C; Cui Y; Liu J; Ma L; Xiong Y; Gong Y; Zhao Y; Zhang X; Chen S; He Q; Zhang J; Liu M; Fan Y
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4054-4066. PubMed ID: 33978830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between PD-L1 expression and
    Chen R; Chen Y; Huang G; Liu J
    Aging (Albany NY); 2019 Dec; 11(24):12270-12277. PubMed ID: 31848322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients.
    Huang Y; Feng M; He Q; Yin J; Xu P; Jiang Q; Lang J
    Medicine (Baltimore); 2017 Apr; 96(17):e6721. PubMed ID: 28445287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.